Influence of the nonergot dopamine agonist piribedil on vigilance in patients with parkinson disease and excessive daytime sleepiness (PiViCog-PD): An 11-week randomized comparison trial against pramipexole and ropinirole

Clinical Neuropharmacology

Volumn 37, Issue 4, 2014, Pages 116-122

  Eggert, Karla ^a   Öhlwein, Christian ^b   Kassubek, Jan ^c   Wolz, Martin ^b   Kupsch, Andreas ^d   Ceballos Baumann, Andres ^e   Ehret, Reinhard ^b   Polzer, Udo ^f   Klostermann, Fabian ^g   Schwarz, Johannes ^h   Fuchs, Gerd ⁱ   Jost, Wolfgang ⁱ   Albert, Anita ^a   Haag, Anja ^a   Hermsen, Anke ^a   Lohmüller, Karin ^j   Kuhn, Katrin ^j   Wangemann, Martina ^j   Oertel, Wolfgang H ^a  

^a PHILIPPS UNIVERSITY MARBURG   (Germany)

^b Department of Neurology University of Ulm ^*  (Germany)

^c UNIVERSITY OF ULM   (Germany)

^d OTTO VON GUERICKE UNIVERSITY   (Germany)

^e TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^f Department of Neurology Asklepios Fachklinikum   (Germany)

^g CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^h Department of Neurology Klinik Haag   (Germany)

ⁱ Parkinson Klinik   (Germany)

^j ALK SCHERAX Arzneimittel GmbH   (Germany)

more..

Author keywords

excessive daytime sleepiness; nonmotor symptoms; Parkinson disease; piribedil; vigilance

Indexed keywords

LEVODOPA; PIRIBEDIL; PRAMIPEXOLE; RASAGILINE; ROPINIROLE; SELEGILINE; ANTIPARKINSON AGENT; BENZOTHIAZOLE DERIVATIVE; INDOLE DERIVATIVE;

ADULT; AGED; ALERTNESS; ARTICLE; CLINICAL FEATURE; CLINICAL GLOBAL IMPRESSION SCALE; CONTROLLED STUDY; DAYTIME SOMNOLENCE; DISEASE SEVERITY; DIZZINESS; DRUG DOSE TITRATION; DRUG EFFECT; DRUG EFFICACY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; EDEMA; EPWORTH SLEEPINESS SCALE; EXCESSIVE DAYTIME SLEEPINESS; FEMALE; FOLLOW UP; HUMAN; INSOMNIA; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NAUSEA; NEUROPSYCHOLOGICAL TEST; OUTCOME ASSESSMENT; PARKINSON DISEASE; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; REACTION TIME; SINGLE BLIND PROCEDURE; SOMNOLENCE; SUSTAINED RELEASE FORMULATION; THERAPY EFFECT; UNIFIED PARKINSON DISEASE RATING SCALE; VERY ELDERLY; ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY; CLINICAL TRIAL; COMPARATIVE STUDY; COMPLICATION; DISORDERS OF EXCESSIVE SOMNOLENCE; DOUBLE BLIND PROCEDURE; DRUG EFFECTS; MIDDLE AGED; SEVERITY OF ILLNESS INDEX;

ADULT; AGED; AGED, 80 AND OVER; ANTIPARKINSON AGENTS; ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY; BENZOTHIAZOLES; DISORDERS OF EXCESSIVE SOMNOLENCE; DOUBLE-BLIND METHOD; FEMALE; HUMANS; INDOLES; MALE; MIDDLE AGED; NEUROPSYCHOLOGICAL TESTS; PARKINSON DISEASE; PIRIBEDIL; REACTION TIME; SEVERITY OF ILLNESS INDEX;

EID: 84925348828     PISSN: 03625664     EISSN: 1537162X     Source Type: Journal    
DOI: 10.1097/WNF.0000000000000041     Document Type: Article

References (43)

1. Aarsland D, Larsen JP, Tandberg E, et al. Predictors of nursing home placement in Parkinson's disease: a population-based study. J Am Geriatr Soc 2000;48:938-942
2. Barone P, Antonini A, Colosimo, et al. The Priamo study: multicenter assessment of nonmotor symptoms and their impact on quality of life in Parkinson's disease. Mov Disord 2009;24:1641-1649
3. Paus S, Brecht HM, Köster J, et al. Sleep attacks, daytime sleepiness, and dopamine agonists in Parkinson's disease. Mov Disord 2003;18:659-667
4. Borek LL, Amick MM, Friedmann JH. Non-motor aspects of Parkinson's diesease. CNS Spectr 2006;11:541-554
5. Allcoock LM, Rowan EN, Steen IN, et al. Impaired attention predicts falling in Parkinson's disease. Parkinsonism Relat Disord 2009;15:110-115
6. Meindorfner C, Körner Y, Möller JC, et al. Driving in Parkinson's disease: mobility, accidents, and sudden onset of sleep at the wheel. Mov Disord 2005;20:832-842
7. Poryazova R, Benninger D, Waldvogel D, et al. Excessive daytime sleepiness in Parkinson's disease: characteristics and determinants. Eur Neurol 2010;63:129-135
8. Drouot X, Moutereau S, Nguyen JP, et al. Low levels of ventricular CSF orexin/hypocretin in advanced Parkinson's disease. Neurology 2003;61: 540-543
9. Zesiewicz TA, Hauser RA. Sleep attacks and dopamine agonists for Parkinson's disease: what is currently known? CNS Drugs 2003;17:593-600
10. Knie B, Mitra MT, Logishetty K, et al. Excessive daytime sleepiness in patients with Parkinson's disease. CNS Drugs 2011;25:203-212
11. Verbaan D, van Rooden SM, Visser M, et al. Nighttime sleep problems and daytime sleepiness in Parkinson's disease. Mov Disord 2008; 23:35-41
12. Wood LD. Clinical review and treatment of select adverse effects of dopamine receptor agonists in Parkinson's disease. Drugs Aging 2010;27: 295-310
13. Monaca C, Duhamel A, Jacquesson JM, et al. Vigilance troubles in Parkinson's disease: a subjective and objective polysomnographic study. Sleep Med 2006;7:448-453
14. Milan MJ,Maiofiss L, Cussac D, et al. Differential actions of antiparkinson agent at multiple classes of monoaminergic receptor. A multivariate analysis of the binding profiles of 14 drugs at 21 native and cloned human receptor subtypes. J Pharmacol Exp Ther 2002;303:791-804
15. Milan MJ. From the cell to the clinic: a comparative review of the partial D2/D3 receptor agonist and alpha2-adrenoreceptor antagonist piribedil, in the treatment of Parkinson's disease. Pharmacol Ther 2010;128:229-273
16. LapizMD,Morilak DA.Noradrenergic modulation of cognitive function in rat prefrontal cortex as measured by attentional set shifting capability. Neuroscience 2006; 137:1039-1049
17. Peretti CS, Gierski F, Harrois S. Cognitive skill learning in healthy older adults after 2 month of double-blind treatment with piribedil. Psychopharmacology (Berl) 2004;176:175-181
18. Gierski F, Peretti CS, Ergis AM. Effects of the dopamine agonist piribedil on prefrontal temporal cortical network function in normal aging as assessed by verbal fluency. Prog Neuropsychopharmacol Biol Psychiatry 2007;31:262-268
19. Schück S, Bentue-Ferrer D, Kleinermans D, et al. Psychomotor and cognitive effects of piribedil, a dopamine agonist in young healthy volunteers. Fundam Clin Pharmacol 2002;16:57-65
20. Castro-Caldas A, Delwaide P, JostW, et al. The Parkinson-Control study: a 1-year randomized, double-blind trial comparing piribedil (150 mg/day) with bromocriptine (25 mg/day) in early combination with levodopa in Parkinson's disease. Mov Disord 2006;21:500-509
21. Fahn S, Marsden CD, Calne DB, et al., eds. Recent Developments in Parkinson's Disease, Vol 2. Florham Park, NJ: Macmillan Health Care Information; 1987:153-163
22. National Institute of Mental Health. Clinical Global Impressions. In: GuyW, ed. ECDEU Assessment for Psychopharmacology. Rev. ed. 1976:218-222
23. Johns MW. A new method for measuring daytime sleepiness: the Epworth sleepiness scale. Sleep 1991;14:540-545
24. Beck AT, Steer RA, Brown GK. Manual for the Beck Depression Inventory-II. San Antonio, TX: The Psychological Corporation; 1996
25. Folstein MF, Folstein SE, McHugh PR. Minimental state. A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 1975;12:189-198
26. Zimmermann P, Fimm B. Testbatterie zur Aufmerksamkeitsprüfung Version 2.1. Psytest, Herzogenrath; 2008
27. Jenkinson C, Peto V, Fitzpatrick R, et al. Self-reported functioning and well-being in patients with Parkinson's disease: comparison of the short-form health survey (SF-36) and the Parkinson's Disease Questionnaire (PDQ-39). Age Ageing 1995;24:505-509
28. Guy W, ed. ECDEU Assessment for Psychopharmacology. Rev. ed. 1976: 218-222
29. Aschenbrenner S, Tucha O, Lange KW. RWT Regensburger Wortflü ssigkeits-Test. 1st ed. Göttingen, Germany: Hogrefe; 2001
30. Helmstaedter C, Lendt M, Lux S. VMLT Verbaler Lern- und Merkfähigkeitstest. 1st ed. Göttingen,Germany:Hogrefe; 2001
31. Bäumler G. Farbe-Wort-Interferenztest (FWIT) nach J. R. Stroop. 1st ed. Göttingen, Germany: Hogrefe; 1985
32. Chaudhuri KR, Pal S, DiMarco A, et al. The Parkinson's disease sleep scale: a new instrument for assessing sleep and nocturnal disability in Parkinson's disease. J Neurol Neurosurg Psychiatry 2002;73:629-635
33. Jost W, Retzow A, Kuhn K. Piribedil-ein non-ergot dopaminagonist mit besonderem rezeptorprofil. Nervenheilkunde 2010;29:571-577
34. Thobois S, Lhommee E, Klinger H, et al. Parkinsonian apathy responds to dopaminergic stimulation of D2/D3 receptors with piribedil. Brain 2013; 136:1568-1577
35. Riekkinen M, Kejonen K, Jäkälä P, et al. Reduction of noradrenaline impairs attention and dopamine depletion slows responses in Parkinson's disease. Eur J Neurosci 1998;10:1429-1435
36. Högl B, Arnulf I, Comella C, et al. Scales to assess sleep impairment in Parkinson's disease: critique and recommendations. Mov Disord 2010;16: 2704-2716
37. Gerlach M, Double K, Arzberger T, et al. Dopamine receptor agonists in current clinical use: comparative dopamine receptor binding profiles defined in the human striatum. J Neural Transm 2003;110: 1119-1127
38. Newman-Tancredi A, Cussac D, Quentric Y, et al. Differential actions of antiparkinson agents at multiple classes of monoaminergic receptor: III. Agonist and antagonist properties at serotonin, 5-HT (1) and 5-HT (2), receptor subtypes. 2002;303: 815-822
39. Peto V, Jenkinson C, Fitzpatrick R. Determining minimally important differences for the PDQ-39 Parkinson's disease questionnaire. Age Ageing 2001;30:299-302
40. Müller T, Benz S, Börnke C, et al. Differential response in choice reaction time following apomorphine based on prior dopaminergic treatment. Acta Neurol Scand 2004;109:348-354
41. Müller T, Benz S, Przuntek H. Choice reaction time after levodopa challenge in parkinsonian patients. J Neurol Sci 2000;181:98-103
42. Müller T, Benz S, Börnke C. Delay of simple reaction time after levodopa intake. Clin Neurophysiol 2001;112:2133-2137
43. Pullman S, Watts R, Juncos J, et al. Dopaminergic effects on simple and choice reaction time performance in Parkinson's disease. Neurology 1988;38:249-254